Acute myelogenous leukemia cells

A detailed study of the 0-linked oligosaccharides present on the surface of normal granulocytes, chronic myelogenous leukemia cells, and acute myelogenous leukemia cells has been completed. Structures were elucidated by f.a.b.-m.s. after permethylation, and methylation analysis before and after specific exo-glycosidase treatments. Some of the components were shown by f.a.b.-m.s. to be poly(N-acetyllactosaminyl) oligosaccharides, for example, 29. 

Moscinski L, Atadja P, Bhalla K (2004) Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 10 4991 997 Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumarawsamy S, Boyapalle S, Atadja P, Seto E, Bhalla K (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280(29) 26729-26734 Bannister AJ, Schneider R, Kouzarides T (2002) Histone methylation Dynamic or static Cell 109 801-806... 

Y.K. Ho, G.S. Smith, M.S. Brown and J.L. Goldstein, Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells, Blood 52 (1978) 1099-1114. 

Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs A cautionary note. Cancer Res 1989 49 5870-5878. 

Lewis, K.A., Holstein, S.A., and Hohl, R.J. (2005). Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leuk Res 29 527-533. 

Kalinkovich A., Tavor S., Avigdor A., et al. (2006) Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells. Cancer Ries. 66, 11013-20. 

Lu, C, Bridget, G., Phillips, G. 2nd, and Abboud, C.N. (2007) Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leukemia Research, 31, 1553-1563. 

Functional CXCR4-expressing microparticles and SDF-1 correlate with drculating acute myelogenous leukemia cells. Cancer Research, 66, 11013—11020. 

Acute leukemias are classified according to their cell of origin. Acute lymphocytic leukemia (ALL) arises from the lymphoid line. Acute nonlymphocytic leukemia (ANLL) or acute myelogenous leukemia (AML) arises from the myeloid line. 

Figure 2. Percentage of CD34+33+117+ cells in acute myelogenous leukemia and myelodysplasia.

Miyamoto, T., Weissman, I. and Akashi, K. (2000) AMLl/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8 21 chromosomal translocation. Proc. Natl. Acad. Scl. USA 97, 7521-7526. 

Novogrodsky A, Dvir A, Ravid A, Shkolnik T, Stenzel KH, Rubin AL, Zaizov R. (1983) Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer 51 9-14. 

The latency period for leukemia was about 20 years, which was 5-10 years shorter than the liver tumors (Frank 1980). The primary forms of leukemia found were erythroleukemia and acute myelogenous leukemia (da Motta et al. 1979 Kamiyama et al. 1988 Mori et al. 1983b). Kamiyama et al. (1988) reported that the damage from Thorotrast may have been due to effects on the hematopoietic stem cell level. 

Cytarabine (cytosine arabinoside, ara-C, Cytosar-U) is an analogue of the pyrimidine nucleosides cytidine and deoxycytidine. It is one of the most active agents available for the treatment of acute myelogenous leukemia. Cytarabine kills cells in the S-phase of the cycle by competitively inhibiting DNA polymerase. The drug must... 

F. Role in therapy According to Micro-medex, single-agent therapy with gem-tuzumab ozogamicin has produced remission in some patients with relapsed or refractory acute myelogenous leukemia. The selective ablation of leukemic cells with this agent is an advantage over conventional chemotherapy. 

Modest but significant improvement has been observed in patients with chronic hepatitis C, Crohn s disease, psoriasis and rheumatoid arthritis after subcutaneous administration of IL-10 in human clinical trials. The systemic administration of IL-10 produces general immune suppression, inhibition of macrophage and T-cell infiltration, less secretion of IL-12 and TNF-a by monocytes and suppression of nuclear factor (NF)-kB induction. In patients with acute myelogenous leukemia, IL-10 increases the serum levels of TNF-a and IL-1 (3. The use of IL-10 for human cancer therapy is under investigation and despite its immunosuppressive effects it may serve a role as a facilitator in preconditioning tumors to be recognized by immune effector cells. 

Chen Y, Wu Y, He J, Chen W. 2002. The experimental and clinical study on the effect of curcumin on cell cycle proteins and regulating proteins of apoptosis in acute myelogenous leukemia. J Huazhong Univ Sci Technolog Med Sci 22 295-298. 

---